Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. - Wikidata - awgldk - TriplyDB

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.

http://www.wikidata.org/entity/Q48956772

about

Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations Observational data: Understanding the real MS world.Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations.Patient perspectives on switching disease-modifying therapies in the NARCOMS registry.A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis Comparative efficacy of switching to natalizumab in active multiple sclerosis.Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US.Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany.Decision-making in Multiple Sclerosis: The Role of Aversion to Ambiguity for Therapeutic Inertia among Neurologists (DIScUTIR MS).Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life.Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy.Current role of chemotherapy and bone marrow transplantation in multiple sclerosis.Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update.Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.The transition from first-line to second-line therapy in multiple sclerosis."No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.Overcoming Therapeutic Inertia in Multiple Sclerosis Care: A Pilot Randomized Trial Applying the Traffic Light System in Medical Education.Use of natalizumab in patients with active relapsing-remitting multiple sclerosis in Kuwait.Predicting PML in natalizumab-treated patients: can we do better?Switching therapies in multiple sclerosis.Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.Cost-effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis.Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.Therapeutic Inertia in the New Landscape of Multiple Sclerosis Care.No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian Neurologists The Role of Prescribing Generic (Non-proprietary) Drugs in the Prevalence of Therapeutic Inertia in Multiple Sclerosis Care

P2860

Q26752859-72BF4631-50C6-4A33-B4BB-52441E4A2FF5 Q30249781-6B1D73F9-AC07-420F-BBA0-88995ECE0CF2 Q30993770-61D43A96-4DA7-4C74-94FC-7D0C3D42BA33 Q33890415-014D230D-3A01-4E77-82B1-C930CF94517F Q34459729-0D561E97-C57D-420A-BEF2-FDCED771B9D8 Q34658763-3A6D592F-2D76-47AC-AD13-FD83A326CC7D Q34737478-41A09B7A-32CB-4041-BB53-00532F294FE8 Q35469575-95A11073-90BB-4550-B38C-7D24AAEE2675 Q35846504-8B8FDDC3-4845-4F47-B65E-F334DE361DD1 Q35884067-1F88E513-DC2B-460E-91F8-CBA0760ECF1C Q36789883-0EB2A90F-6544-4C39-8765-C05DB6726926 Q37412487-D60D635B-8750-4881-9F27-7855603BC5CE Q37422818-B1A264F4-E3DD-4B8A-95A8-293883CBAA9E Q37626336-160EC06D-3907-457F-9573-6531440C68B8 Q37672368-B91B83BC-5833-4CE8-AEF7-D22CB4FF6377 Q37696989-6F21FC40-FBA2-4202-9E66-F7BF30A4B85F Q38163046-2307BBE5-2C5A-4EF3-AA3D-A7E84B1DF024 Q38268313-20C446F7-DA7A-4920-B0F3-0D5AD9C31177 Q38616689-47047A6E-A171-4ED2-BEB7-634D9849DB68 Q38946338-EB1A6CFE-6ED3-4D0E-B6EE-D4755984784D Q39021942-E054342A-AC1D-494C-85C5-731301EBA25B Q41014662-2DC69453-936A-40ED-AE88-233294EE7859 Q41185260-9C8752C6-914C-41CA-82BF-C3F26A3DDEC1 Q41488417-5926E93F-C7C2-4E3F-81C5-DBA5995CDA99 Q42288520-55F2BC7A-9856-4EEA-9151-175EAB1FB1F5 Q44495152-65B36EEA-4A15-47A4-8B6D-C8F6E94826B1 Q45977173-BFE3B189-8614-4094-AE12-43D98E0E713A Q46870849-B10818D0-D4F5-4FEE-B706-C4BFE867CF5B Q47865523-B963A89D-F039-45C8-A261-397EB1101FE7 Q48204088-970131A8-F7CB-4F9E-9D0B-385F2118A5E1 Q48858478-2CF132C4-6B8E-484E-B408-D871B031F903 Q51167980-50B4D63F-1D47-46FF-B55E-9633D11DF2E0 Q52608604-14BF3369-F212-4FA6-B178-7D4464340753 Q52641471-600FED20-DB58-4F5C-807F-7D1F5E646026 Q57492439-51A59C9A-EF49-4A00-ABD6-62C8DD4B0721 Q58122615-994A1751-FC87-427B-93C5-F69CF95A86F3

P2860

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.

http://www.wikidata.org/entity/Q48956772

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Escalation to natalizumab or s ...... relapsing multiple sclerosis.

@en

Escalation to natalizumab or s ...... relapsing multiple sclerosis.

@nl

type

label

Escalation to natalizumab or s ...... relapsing multiple sclerosis.

@en

Escalation to natalizumab or s ...... relapsing multiple sclerosis.

@nl

prefLabel

Escalation to natalizumab or s ...... relapsing multiple sclerosis.

@en

Escalation to natalizumab or s ...... relapsing multiple sclerosis.

@nl

P1433

Q48956772-ED95134B-E3CC-4221-8D59-B361082E1600

P1476

Q48956772-E85B3432-5965-4EC4-94A9-9D89FBE5FD00

P2093

Q48956772-405D9FEB-0611-4415-BE4E-4F81C8014A45

Q48956772-58AE11B3-D8DE-4116-98BA-C0F64BC01651

Q48956772-7D3F4AE0-287E-4DD9-B53D-D784826E9725

Q48956772-89D6D2B2-FAD0-4A0B-9BB1-4942F5F361D5

Q48956772-AB1B3A15-B0A3-44C9-BEFA-108F24E08D5F

Q48956772-B99139AC-C80A-48C0-A67C-51D16DE70759

Q48956772-DF966AC5-B09F-40C0-9C00-D30B901D9655

Q48956772-E4A95352-1ECD-4298-B5A2-EADA1276DB09

P2860

Q48956772-02DD0A12-D121-4D17-9D15-777E308D1256

Q48956772-059A83BD-76FF-4356-9C14-EB7296180B9F

Q48956772-0AC11FAB-F6A6-42DD-A1C9-ED3C47386FCC

Q48956772-27F12E3F-23F6-4FD4-AB2E-CB06B8C895E4

Q48956772-29185C20-996A-40B7-B32E-2B6B4711B919

Q48956772-2F22F103-01D1-4420-B324-7175D5B49F1B

Q48956772-306BADBE-30BF-4439-9E2C-0D65E6E471B1

Q48956772-31C4FAC1-B308-4512-98D8-F9868085CCD1

Q48956772-3544A1FB-7C53-409D-8894-52B98AE29EEF

Q48956772-3BBC035B-4889-41D5-BF2A-E799FFD2BE7E

P304

Q48956772-146EFFCD-E290-4125-8DC0-6EA8B4A02458

P31

Q48956772-9D08187E-C433-4333-A21D-1FA059AAE5A7

P356

Q48956772-89647F06-C9F4-44DC-903A-E1EB22F87718

P433

Q48956772-AE0265C2-E19A-4958-B89B-C999C11F4F75

P478

Q48956772-82E516EB-9213-48A0-9AF5-3E9E3CAE97B9

P577

Q48956772-67355C7C-4DE0-4742-904D-182777AB6F3B

P698

Q48956772-5124C697-D0C1-4960-8CD1-EC0F9B59D9CB

P921

Q48956772-40CD70E6-FC8E-4A3F-A834-D594BF5CC931

P356

1352458511417481

P1433

Multiple Sclerosis Journal

P1476

Escalation to natalizumab or s ...... relapsing multiple sclerosis.

@en

P2093

Carlo Pozzilli

http://www.w3.org/2001/XMLSchema#string

Claudio Gasperini

http://www.w3.org/2001/XMLSchema#string

Costanza Giannì

http://www.w3.org/2001/XMLSchema#string

Giovanna Borriello

http://www.w3.org/2001/XMLSchema#string

Laura De Giglio

http://www.w3.org/2001/XMLSchema#string

Laura Leonardi

http://www.w3.org/2001/XMLSchema#string

Luca Prosperini

http://www.w3.org/2001/XMLSchema#string

Simonetta Galgani

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis.

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina.

P304

64-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1352458511417481

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21828195

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis